2023 Inaugural Summit
Theme: “From Applying Innovation to Building an Innovative Culture”
Date: November 9, 2023 Time: 8:00 AM - 5:00 PM Location: Regeneron Pharmaceuticals, 777 Old Saw Mill River Rd, Tarrytown, NY 10591 Format: Hybrid (In-person: ~100 attendees, Virtual participation available)
Event Overview
The inaugural Statistical Innovation Community Summit marked a historic milestone in bringing together statisticians from the FDA, academia, and over 20 pharmaceutical companies to discuss how statistical innovation can optimally enhance medical product development.
Program Agenda
7:30 AM - 8:00 AM: Registration and Breakfast
8:00 AM - 8:30 AM: Opening Remarks
Chair: Chenguang Wang
9:00 AM - 11:30 AM: Keynote Session
Title: “Maximizing the Impact of Innovative Statistical Methods in Partnership with Health Agencies”
Organizers: Satrajit Roychoudhury, Chenguang Wang
Distinguished Keynote Speakers
- John Scott (FDA): “FDA Complex Innovative Trial Design (CID) Program”
- Ying Yuan: “BOIN: How it was Developed in Collaboration with the FDA”
- Neal Thomas: “Dose-finding with Emax Modeling: Experience with FDA Methodology Qualification”
- Jose Pinheiro (Johnson & Johnson)
11:30 AM - 1:00 PM: Lunch and Networking Mixer
1:00 PM - 2:15 PM: Session I - Statistical Innovation in Action
Organizers: Kentaro Takeda, Chenguang Wang, May Mo
Case studies demonstrating the potential of innovative approaches:
Featured Speakers
- Haoda Fu (Eli Lilly)
- Binbing Yu (AstraZeneca)
- Li Wang (AbbVie)
- Inna Perevozskaya (GSK)
- Jiawen Zhu (Genentech)
- Jian Zhu (Servier)
- Ron Yu’s team member (Gilead) - Open-source software
2:15 PM - 3:30 PM: Session II - Maximizing Impact as Core Organization
Organizers: Elena Polverejan, Satrajit Roychoudhury, Ron Yu
Chair: Philip He (Daiichi Sankyo) Moderator: Elena Polverejan
Business models, roles, and responsibilities within organizations:
Organizational Representatives
- Ron Yu (Gilead)
- Kentaro Takeda (Astellas)
- Jose Pinheiro (Johnson & Johnson)
- May Mo (Amgen)
- Demissie Alemayehu (Pfizer)
- David Ohlssen (Novartis)
- Yongming Qu (Eli Lilly)
3:30 PM - 3:45 PM: Coffee Break
3:45 PM - 4:45 PM: Panel Discussion Session III
Organizers: Jose Alvir, Jinglin Zhong, Marcia Levenstein
Moderator: Jinglin Zhong
Topic: “How can we more effectively organize the statistical innovation community and empower all members within it?”
Panelists
- Lei Nie (FDA)
- Keaven Anderson (Merck)
- Ram Tiwari (Bristol Myers Squibb)
- Vlad Dragalin (Johnson & Johnson)
- Olga Marchenko (Bayer)
- Sammi Tang (Servier)
- Minghui Chen (University of Connecticut)
- Claude Petit (Astellas)
- Scott Berry (Berry Consultants)
4:45 PM - 5:00 PM: Closing Remarks
Chair: Satrajit Roychoudhury
Summit Impact and Recognition
Community Response
The summit’s success demonstrated the statistical innovation community’s:
- Enthusiasm and energy throughout the organization process
- Sophistication in addressing complex methodological and operational challenges
- Dedication to advancing pharmaceutical statistics
Key Outcomes
The summit established important principles for the statistical innovation community:
- Business Integration: Innovation groups must understand business needs and deliver measurable value
- Partnership Focus: Must collaborate with all functional teams in pharmaceutical organizations
- Recognition Imperative: Community requires acknowledgment from both statistical field and pharmaceutical organizations
- Training and Development: Need for appropriate training programs and career paths
Future Vision
The summit positioned statistical innovation as the fourth cornerstone of pharmaceutical statistics organizations, alongside:
- Data Management
- Programming
- Biostatistics
Organizing Committee
Leadership Team
- Co-Chairs: Chenguang Wang (Regeneron), Satrajit Roychoudhury (Pfizer)
- Committee Members: May Mo, Elena Polverejan, Kentaro Takeda, Xiaolong (Ron) Yu, Jinglin Zhong, Jose Ma. Alvir, Marcia Levenstein
Institutional Support
- Regeneron Leadership: Jeen Liu, Bret Musser, Ned Braunstein
- Sponsor: ASA New York Metro Area Chapter
Legacy and Continuation
The inaugural summit established the foundation for:
- Annual summit series
- Community hub for statistical innovation
- Recognition pathway for innovation statisticians
- Collaborative framework between industry, academia, and regulatory agencies
The 2023 Inaugural Summit was a pivotal moment in establishing the Statistical Innovation Community as a recognized and vital part of pharmaceutical research and development.